title: Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer.
abstract: OBJECTIVE
  To report the results of treatment with intraluminal brachytherapy (ILRT) after concurrent chemoradiotherapy for esophageal carcinoma with respect to disease free survival (DFS), dysphagia free interval (DFI), and complications of treatment.
  
  
  METHODS
  The study retrospectively analyzed the records of 26 eligible patients with nonmetastatic carcinoma of the esophagus treated with definitive chemoradiotherapy followed by ILRT between 2008 and 2011. The DFS and DFI were estimated and factors likely to influence them were analyzed.
  
  
  RESULTS
  Nineteen (73%) patients were males. The mean age at presentation was 60 years (range: 47-90 years). All the patients had squamous cell carcinomas. Following treatment, the median DFS was 12.7 months (range: 0-27 months). Sixteen patients (61.5%) had local control of their disease, while one had residual disease at completion of treatment. Other than three patients who were not evaluated for recurrent dysphagia, six (23.1%) had proven local recurrence on follow-up. The estimated mean DFI was 13.8 months (range: 0-27 months). One patient died of tracheoesophageal fistula following treatment. On statistical analysis, only the location of tumor was prognostically significant, with lower third tumors performing worse. Other probable predictors of poor outcome included large volume (> 40 cc), tumor length (> 6 cm), and eccentric location.
  
  
  CONCLUSIONS
  ILRT boost following concurrent chemoradiotherapy is well tolerated and potentially improves outcomes. It might be beneficial in selected patients with esophageal carcinoma. Further studies are required to identify its role in definitive treatment.
authors.forename: Krishna
authors.initials: K
authors.lastname: Sharan
authors.forename: Donald Jerard
authors.initials: DJ
authors.lastname: Fernandes
authors.forename: P U
authors.initials: PU
authors.lastname: Prakash Saxena
authors.affiliation: Department of Radiotherapy, Shirdi Saibaba Cancer Hospital and Research Centre, Manipal, Karnataka, India.
authors.forename: Sourjya
authors.initials: S
authors.lastname: Banerjee
authors.forename: Brijesh
authors.initials: B
authors.lastname: Sathian
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome